|
|
|
|
|
|
|
04.11.25 - 14:03
|
Exagen Inc. Reports Strong Q3 2025 Results (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates....
|
|
|
23.10.25 - 15:18
|
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois....
|
|
|
21.10.25 - 22:09
|
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15.07.25 - 22:09
|
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT)....
|
|
|
|
|
|
|
09.05.25 - 22:09
|
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter′s Option to Purchase Additional Shares (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025....
|
|
|
|
|
08.05.25 - 14:33
|
Exagen Inc. Prices Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satisfaction of customary closing conditions....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
